First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

HER2-positive Gastric Cancer Clinical Trial

— RCTS  

Official title:

A Prospective, Multicenter, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Positive Advanced Gastric Cancer With Disitamab Vedotin in Combination With Tirelizumab and S-1

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05586061
• Other study ID #: RCTS
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 1, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: August 2022
• Source: Qilu Hospital of Shandong University
• Contact: Lian Liu, Doctor
• Phone: 0531-82169851
• Email: tounao[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 55
• Est. completion date: December 31, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Aged18-75 years, gender is not limited;

2. Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;

3. HER2 was detected as 2+or 3+ by immunohistochemistry(IHC) ;

4. Has at least 1 measurable lesion as determined by RECIST 1.1;

5. There is no systematic treatment in the past, or the patient has received neoadjuvant/adjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

7. Adequate organ function:

1. Bone marrow function: i. Hemoglobin count (HGB)=80g/L; ii. Neutrophil count (NE)=1.5×109/L; iii. White blood cell count (WBC)=3.5×109/L; iv. Platelet count (PLT)=100×109/L;

2. Liver function: i. Serum total bilirubin (TBIL)=1.5×ULN; ii. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)=3×ULN, patients with liver metastasis=5×ULN;

3. Kidney function: Blood creatinine (Cr) =1.5×ULN or Cockcroft Gault formula = 60 mL/min;

4. Cardiac function: New York Heart Association (NYHA) classification<Grade 3; Left ventricular ejection fraction=50%;

8. The life expectancy is at least 3 months;

9. Female of childbearing age must have taken reliable contraceptive measures or conducted a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the test drug; For male, they must agree to use appropriate methods of contraception during the trial and 8 weeks after the last administration of the trial drug;

10. Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.

Exclusion Criteria:

1. Allergy to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;

2. Cardiovascular and cerebrovascular events that are not well controlled, such as:

1. NYHA grade 2 or above heart failure;

2. Unstable angina pectoris;

3. Myocardial infarction occurred within 1 year;

4. Supraventricular or ventricular arrhythmia with clinical significance needs treatment or intervention;

5. Cerebral hemorrhage and cerebral infarction (except for lacunar cerebral infarction without symptoms and without treatment);

6. Serious cardiovascular and cerebrovascular events occurred within 12 months;

7. Uncontrolled hypertension, i.e. systolic blood pressure>140 mmHg or diastolic blood pressure>90 mmHg after single drug treatment;

8. Patients with history of arterial thrombosis or deep vein thrombosis within 6 months before recruitment, or with evidence of bleeding tendency or medical history within 2 months before recruitment, regardless of the severity;

9. Stroke event or transient ischemic attack occurred within 12 months before recruitment;

3. Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks.

4. Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);

5. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases;

6. Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.Have a history of active tuberculosis infection = 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment;

7. Brain metastasis or leptomeningeal metastasis;

8. Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the trial drug;

9. Has a second clinically detectable primary malignant tumor at the time of recruitment, or there were other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);

10. Any major surgery was performed = 28 days before the first trial drug administration;

11. History of allogeneic stem cell transplantation or organ transplantation;

12. Duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;

13. Live vaccine was inoculated within 4 weeks (inclusive) before the first administration of the trial drug, not including seasonal influenza vaccines but intranasal vaccine.

14. Has other factors that may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;

15. Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;

16. Others conditions do not meet the inclusion according to the judgment of the investigator.

Related Conditions & MeSH terms

• HER2-positive Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Disitamab vedotin
Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
• Tislelizumab
Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
• S1
S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.

Locations

Country	Name	City	State
China	Central Hospital Affiliated to Shandong First Medical University	Jinan	Shandong
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry	Jinan	Shandong
China	The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)	Jinan	Shandong
China	Qingdao Municipal Hospital (Group)	Qingdao	Shandong
China	The Affiliated Hospital of Qingdao University	Qingdao	Shandong
China	Yantai Yuhuangding Hospital	Yantai	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate (ORR)	The proportion of subjects with complete response (CR) and partial response (PR) in total subjects	6 months after the last subject participating in
Secondary	progression-free survival (PFS)	Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first	12 months after the last subject participating in
Secondary	overall survival (OS)	OS is defined as the time from the starting date of study drug to the date of death due to any cause.	12 months after the last subject participating in
Secondary	disease control rate (DCR)	The proportion of subjects with complete response (CR) and partial response (PR) and stable disease(SD)in total subjects	12 months after the last subject participating in
Secondary	duration of response (DOR)	DOR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first.	12 months after the last subject participating in